Physician profile
David E Borg
NPI 1578502621
$1,946.02
in general payments reported to CMS, 2019-2025
22 companies · $30.15 in 2025
The $30.15 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $372 · 2020: $349 · 2021: $395 · 2022: $350 · 2023: $432 · 2024: $17.84 · 2025: $30.15.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $480.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $479.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $961.10 | 2019-2023 | Prolia, Evenity, Repatha |
| Abbvie INC. | $158.19 | 2021-2023 | Vraylar, Ubrelvy, Dalvance |
| Sunovion Pharmaceuticals INC. | $141.33 | 2019-2022 | |
| Novo Nordisk INC | $136.27 | 2019-2023 | Ozempic, Rybelsus |
| Pfizer INC. | $114.58 | 2019-2023 | |
| Mylan Specialty L.P. | $60.17 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $54.13 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $39.60 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $38.99 | 2023-2024 | Rexulti, Abilify Asimtufii |
| Lilly USA, LLC | $35.16 | 2021-2025 | Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $31.86 | 2020-2023 | |
| Organogenesis INC. | $23.66 | 2022 | |
| Boston Scientific Corporation | $22.03 | 2022 | |
| Nevro Corp. | $17.08 | 2022 | |
| Sanofi Pasteur INC. | $16.76 | 2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $16.59 | 2021 | |
| Genzyme Corporation | $15.15 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.20 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $13.92 | 2025 | Uzedy |
| Janssen Pharmaceuticals, INC | $12.64 | 2019 | |
| Acadia Pharmaceuticals INC | $11.59 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Borg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.